Forschung
Our research @Brain Tumor Translational Research Group >
Most Important Publications
Ebrahimi A, Herrlinger U, Waha A, Kaluza L, Pietsch T. Methylation class oligosarcoma may encompass IDH-wildtype gliomas. Acta Neuropathol. 2023 Mar;145(3):361-364.
Venkataramani V, Schneider M, Giordano FA, Kuner T, Wick W, Herrlinger U, Winkler F. Disconnecting multicellular networks in brain tumours. Nat Rev Cancer 22:481-491, 2022
Schneider M, […], Herrlinger U, Heiland DH. Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. Neuro Oncol, 2021 Apr 17:noab092. doi: 10.1093/neuonc/noab092. Online ahead of print.
Weller J, [...] Herrlinger U , Schäfer N. Health-related quality of life and neurocognitive functioning in the randomised phase III CeTeG/NOA-09 trial for newly diagnosed MGMT-hypermethylated glioblastoma. Lancet Oncol, 20:1444-1453, 2019
Herrlinger U, Tzaridis T, Mack F. et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. Lancet 393: 678–88, 2019
Schäfer N, Proescholdt M, [...] Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol 20:975-985, 2018
van den Bent MJ, Baumert B, […] Herrlinger U, [...] Kros JM. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 390:1645-1653, 2017.
Herrlinger U, et al. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol 34:1611-9, 2016
Herrlinger U, Jones DTW, Glas M, et al. Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol 131:309-319, 2016.
Stuplich M, Hadizadeh DR, Kuchelmeister K, […], Herrlinger U. Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide. J Clin Oncol 30:e180-3, 2012
Glas M, Bähr O, Felsberg J, […], Herrlinger U. NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 70:445-53, 2011
Thiel E, Korfel A, Martus P, […], Herrlinger U, […] Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036-47, 2010
Glas M, Happold C, Rieger J, [...], Herrlinger U. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 27:1257-61, 2009
Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24:4412-7, 2006
Herrlinger U, Küker W, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57:843-7, 2005
Herrlinger U et al. NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 51:247-52, 2002
